Sunshine Biopharma, Inc. (SBFM) Financial Ratios
18 years of historical data (2007–2024) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.03
↓-100% vs avg
5yr avg: 9.23
30Y Low0.1·High36.1
ROE
↑
-23.0%
↓+99% vs avg
5yr avg: -1541.1%
30Y Low-372%·High-21%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SBFM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Sunshine Biopharma, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $757819 | $2M | $7M | $10M | $8M | $1M | $2M | $487M | $20.8B | $480000 | $795M |
| Enterprise Value | $-7976230 | $-6628802 | $-9029047 | $-11345979 | $7M | $2M | $2M | $488M | $20.8B | $659518 | $796M |
| P/E Ratio → | -0.15 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.02 | 0.06 | 0.27 | 2.24 | 33.42 | 19.04 | 75.21 | 1090.09 | — | — | 465199.06 |
| P/B Ratio | 0.03 | 0.09 | 0.31 | 0.45 | 36.06 | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SBFM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.19 | -0.37 | -2.61 | 32.78 | 31.97 | 107.17 | 1091.96 | — | — | 465837.10 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
SBFM Profitability
Margins and return-on-capital ratios measuring operating efficiency
Sunshine Biopharma, Inc. earns an operating margin of -16.7%. Operating margins have expanded from -621.3% to -16.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -23.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 30.6% | 30.6% | 34.6% | 39.0% | 48.4% | 63.8% | 47.7% | 12.5% | — | — | -22423.9% |
| Operating Margin | -16.7% | -16.7% | -19.9% | -621.3% | -1068.2% | -807.8% | -3037.9% | -261.0% | — | — | -45667.4% |
| Net Profit Margin | -14.7% | -14.7% | -18.7% | -615.4% | -5444.2% | -3898.7% | -7860.9% | -482.1% | — | — | -96779.9% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -23.0% | -23.0% | -21.0% | -244.9% | -5875.4% | — | — | — | — | — | — |
| ROA | -17.7% | -17.7% | -15.8% | -168.5% | -765.7% | -486.9% | -266.8% | -307.1% | -646.3% | -948.0% | -404.8% |
| ROIC | -42.9% | -42.9% | -116.9% | -6399.5% | -10489.8% | — | -133.4% | -193.8% | -1409.2% | -322.1% | -264.8% |
| ROCE | -25.2% | -25.2% | -21.5% | -218.4% | -231.7% | — | — | -498.5% | — | — | — |
SBFM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $10M exceeds total debt of $952480, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.03 | 0.04 | 8.98 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.37 | -0.74 | -0.97 | -0.69 | — | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -662.41 | -662.41 | -34.85 | -685.10 | -7.42 | -3.43 | -5.54 | -7.32 | -8.18 | -28.59 | -2.54 |
Net cash position: cash ($10M) exceeds total debt ($952480)
SBFM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Sunshine Biopharma, Inc.'s current ratio of 4.11x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.33x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 3.94x to 4.11x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.11 | 4.11 | 4.48 | 3.94 | 24.07 | 0.98 | 0.08 | 0.23 | 0.16 | 0.21 | 0.04 |
| Quick Ratio | 2.33 | 2.33 | 3.45 | 3.47 | 22.91 | 0.95 | 0.06 | 0.23 | 0.17 | 0.21 | 0.04 |
| Cash Ratio | 1.53 | 1.53 | 2.93 | 3.15 | 22.42 | 0.95 | 0.06 | 0.13 | 0.14 | 0.21 | 0.04 |
| Asset Turnover | — | 1.14 | 0.88 | 0.15 | 0.10 | 0.07 | 0.22 | 0.39 | — | — | 0.00 |
| Inventory Turnover | 2.15 | 2.15 | 2.75 | 0.81 | 1.12 | 1.09 | 0.69 | — | — | — | — |
| Days Sales Outstanding | — | 40.49 | 38.67 | 160.59 | 12.46 | 9.79 | 7.43 | — | — | — | 664.82 |
SBFM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Sunshine Biopharma, Inc. returns 100.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 100.0% | 100.0% | 8.2% | 1.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 100.0% | 100.0% | 8.2% | 1.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $701749 | $12165 | $7590 | $1306 | $866 | $1765 | $15234 | $43632 | $3 | $1528 |
Peer Comparison
Compare SBFM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SBFMYou | $757819 | -0.1 | — | — | 30.6% | -16.7% | -23.0% | -42.9% | — |
 CRVS | $1B | -27.5 | — | — | — | — | -32.6% | -78.1% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 NUVB | $2B | -8.0 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 TPVG | $243M | 4.9 | 9.1 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 SNDX | $2B | -6.2 | — | — | 96.0% | -158.4% | -161.8% | -54.2% | — |
 KALA | $617676 | -0.0 | — | — | — | — | -388.3% | — | — |
 ALDX | $104M | -1.8 | — | — | — | — | -58.5% | -369.4% | — |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 ICLR | $10B | 13.1 | 7.9 | 8.5 | 29.4% | 13.3% | 8.4% | 6.5% | 2.3 |
 MEDP | $12B | 28.1 | 21.3 | 18.0 | 30.1% | 21.1% | 70.2% | 154.9% | 0.4 |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 18 years · Updated daily
See SBFM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SBFM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SBFM vs CRVS
Side-by-side business, growth, and profitability comparison vs Corvus Pharmaceuticals, Inc..
Start ComparisonSBFM — Frequently Asked Questions
Quick answers to the most common questions about buying SBFM stock.
What is Sunshine Biopharma, Inc.'s P/E ratio?
Sunshine Biopharma, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is Sunshine Biopharma, Inc.'s ROE?
Sunshine Biopharma, Inc.'s return on equity (ROE) is -23.0%. The historical average is -187.3%.
Is SBFM stock overvalued?
Based on historical data, Sunshine Biopharma, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Sunshine Biopharma, Inc.'s profit margins?
Sunshine Biopharma, Inc. has 30.6% gross margin and -16.7% operating margin.